Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer

Eur Urol. 2019 Dec;76(6):870-871. doi: 10.1016/j.eururo.2019.07.019. Epub 2019 Jul 25.

Authors

Charlotte S Voskuilen¹, Michiel S van der Heijden², Bas W G van Rhijn³

Affiliations

¹ Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
² Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
³ Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: b.v.rhijn@nki.nl.

PMID: 31351667
DOI: 10.1016/j.eururo.2019.07.019

No abstract available

Publication types

Comment

MeSH terms

Cisplatin
Deoxycytidine / analogs & derivatives
Gemcitabine
Humans
Neoadjuvant Therapy*
Prospective Studies
Urinary Bladder Neoplasms*

Substances

Deoxycytidine
Cisplatin
Gemcitabine